Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02025972
Other study ID # UCBCP
Secondary ID
Status Completed
Phase N/A
First received December 29, 2013
Last updated October 10, 2017
Start date December 2013
Est. completion date November 15, 2015

Study information

Verified date October 2017
Source Bundang CHA Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This open-label study aims to analyze cytokines related to clinical outcomes of allogeneic umbilical cord blood therapy for children with cerebral palsy.


Description:

Cerebral palsy (CP) is a group of neurodevelopmental conditions with abnormal movement and posture resulted from a non-progressive cerebral disturbance. It is the most common cause of motor disability in childhood. Most therapies are palliative rather than restorative. Umbilical cord blood (UCB) may be used as restorative approach for children with CP.

Many experimental animal studies have revealed that UCB is beneficial to improve and repair neurological injuries.

Based on animal studies and some clinical trials, UCB is suggested as a potential therapy for children with CP. This study was designed to find cytokines relevant to UCB therapy.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date November 15, 2015
Est. primary completion date November 15, 2015
Accepts healthy volunteers No
Gender All
Age group N/A to 15 Years
Eligibility Inclusion Criteria:

- Diagnosed with cerebral palsy

- Age of =15 years

- Mismatch in HLA-A, B, and DR =2, and total nucleated cell count =3x10^7/kg. If the cell count is less than given values, more than 1 unit could be used.

- Decision of participation in the study by and acquisition of informed consent from the subject's representative

- Willingness and ability to be hospitalized according to the schedule specified in the protocol and continue the study for 12 months after study entry

Exclusion Criteria:

- Current aspiration pneumonia

- Known genetic disease

- History of hypersensitivity reaction to any study drugs pertinent to the study

- Patient with severe seizure disease who has clinical convulsion despite combination therapy with 3 or more agents

- Uncontrolled hypertension defined as systolic blood pressure >115 mmHg and/or diastolic blood pressure >70 mmHg

- Hepatic impairment defined as asparate aminotransferase (AST) >55 IU/L and/or alanine aminotransferase (ALT) >45 IU/L

- Renal impairment defined as creatinine (Cr) =1.2 mg/dL

- Presence of diagnosed or suspected malignant tumor and/or hematologic malignancy

- Non-compliance with study visits specified in the protocol or unwillingness of care-giver due to lack of understanding of the patient

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Allogeneic umbilical cord blood therapy


Locations

Country Name City State
Korea, Republic of CHA Bundang Medical Center, CHA University Seongnam-si Gyeonggi-do

Sponsors (2)

Lead Sponsor Collaborator
MinYoung Kim, M.D. CHA University

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Cytokine analysis Cytokine analysis 12 months
Primary Changes in Standardized Gross Motor Function GMFM (Gross Motor Function Measure) is a standardized measurement tool for assessing gross motor function consisting of sub-scales; lying & rolling, sitting, crawling & kneeling, standing, walking, running & jumping (range: 0~100, higher value means better gross motor function). Baseline - 3 months - 6 months - 12months
Primary Changes in Motor Performance GMPM (Gross Motor Performance Measure) is a standardized measurement tool for assessing quality of movement regarding 3 properties of 5 ones; alignment, coordination, dissociated movement, stability, and weight shift (range: 0~100, higher value means better motor quality). Baseline - 3 months - 6 months - 12 months
Primary Changes in Cognitive Neurodevelopmental Outcome Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Mental Scale (range: 0~178; worst: 0, best: 178) Baseline - 3 months - 6 months - 12 months
Primary Changes in Motor Neurodevelopmental Outcome Korean version of Bayley Scale of Infant Development-II (K-BSID-II) Motor Scale (range: 0~112; worst: 0, best: 112) Baseline - 3 months - 6 months - 12 months
Secondary Changes in Gross Motor Function Classification System GMFCS (Gross Motor Function Classification System) is a five-level classification system based on self-initiated movement, with emphasis on sitting, transfers, and mobility (level I: walks without limitations, ll: walks with limitations, III: walks using a hand-held mobility device, IV: self-mobility with limitations, V: transported in a manual wheelchair). Baseline - 3 months - 6 months - 12 months
Secondary Changes in Functional Independence in Daily Activities WeeFIM (Functional Independence Measure for Children) measures functional independence in daily activities. WeeFIM contains 18 items and each item is ranked from complete dependence (scored as 1) to complete independence (scored as 7). The range is from 18 to 126 and higher score means more independent performance in daily activities. Baseline - 3 months - 6 months - 12 months
Secondary Changes in Functional Performance in Daily Activities Pediatric Evaluation of Disability Inventory (PEDI) is used to assess functional performance in daily activities in children (All values are adjusted and higher value means better functional performance, 0 - worst, 100 - best). PEDI consists of 2 scales such as Functional Skill Scale (FSS) and a Caregiver Assistance Scale (CAS) and each scale is composed of 3 domains including self care, mobility, and social function. Baseline - 3 months - 6 months - 12 months
Secondary Changes in Upper Extremity Function QUEST (Quality of Upper Extremity Skills Test) is a standardized measurement tool for assessing upper extremity function consisting of sub-scales; dissociated movement, grasps, weight bearing, and protective extension. QUEST ranges from 0 (or below 0 in grasp section) to 100 and higher values mean better upper extremity function. Baseline - 3 months - 6 months - 12 months
Secondary Changes in Visual Perception Test Visual perception function will be assessed with one of 3 tools such as DTVP (Developmental Test of Visual Perception), MVPT (Motor-free Visual Perception Test), and VMI (Visual-Motor Integration, Visual Perception and Motor Coordination). Higher value means better visual perception ability. Baseline - 3 months - 6 months - 12 months
Secondary Changes in Selective Movement of Lower Extremity SCALE (Selective Control Assessment of Lower Extremity) is a measurement tool of selective movement of hip, knee, ankle, subtalar joint and toes. Selective voluntary motor control is graded at each joint as normal (2 points), impaired (1 point) or unable (0 point). Baseline - 3 months - 6 months - 12 months
Secondary Changes in Spasticity Muscle spasticity of biceps, hip adductors, hamstrings and heel cords is graded according to modified Ashworth scale (MAS). Baseline - 3 months - 6 months - 12 months
Secondary Changes in Dynamic Component of Spasticity Dynamic component of spasticity in bilateral hamstrings is graded using modified Tardieu scale (MTS). Baseline - 3 months - 6 months - 12 months
Secondary Changes in Muscle Strength Muscle strength is measured using summated scores of manual muscle test (zero=0, trace=1, poor=2, fair=3, good=4, normal=5) for flexors, extensors, abductors, and adductors of bilateral shoulder and hip joints; flexors and extensors of bilateral elbow, wrist, and knee; dorsiflexors and plantar flexors of the ankles (range: 0 ~ 160). Higher score means stronger muscle power. Baseline - 3 months - 6 months - 12 months
Secondary Changes in Brain MRI Diffusion Tensor Image (DTI) of brain MRI (magnetic resonance imaging) provides quantitative information about the microscopic integrity of white matter. White matter normally possesses a high degree of diffusion anisotropy than gray matter. Fractional anisotropy (FA) will be measured and it ranges from 0 to 1. Higher FA value means more integrity of white matter. Baseline - 12 months
Secondary Changes in Brain 18F-FDG PET 18F-FDG PET (Positron emission tomography with fluorine-18-fluorodeoxyglucose) imaging will be performed twice prior to and 12 months after UCB therapy. Baseline - 12 months
Secondary Changes in EEG Electroencephalography (EEG) will be performed twice prior to and 12 months after UCB therapy. Baseline - 12 months
Secondary Changes in EP Median, tibial somatosensory evoked potential (SEP), visual evoked potential (VEP), auditory evoked potential (AEP) will be performed twice prior to and 12 months after UCB therapy. Baseline - 12 months
Secondary Number of adverse events and participants with those adverse events The numbers of adverse events and subjects with those serious adverse events within each group; A serious adverse event is any untoward medical occurrence that at any dose: results in death or is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, or causes a congenital anomaly/birth defect. 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT05317234 - Genetic Predisposition in Cerebral Palsy N/A
Recruiting NCT05576948 - Natural History of Cerebral Palsy Prospective Study
Completed NCT04119063 - Evaluating Wearable Robotic Assistance on Gait Early Phase 1
Completed NCT03264339 - The Small Step Program - Early Intervention for Children With High Risk of Developing Cerebral Palsy N/A
Completed NCT05551364 - Usability and Effectiveness of the ATLAS2030 Exoskeleton in Children With Cerebral Palsy N/A
Completed NCT03902886 - Independent Walking Onset of Children With Cerebral Palsy
Recruiting NCT05571033 - Operant Conditioning of the Soleus Stretch Reflex in Adults With Cerebral Palsy N/A
Not yet recruiting NCT04081675 - Compliance in Children With Cerebral Palsy Supplied With AFOs
Completed NCT02167022 - Intense Physiotherapies to Improve Function in Young Children With Cerebral Palsy N/A
Completed NCT04012125 - The Effect of Flexible Thoracolumbar Brace on Scoliosis in Cerebral Palsy N/A
Enrolling by invitation NCT05619211 - Piloting Movement-to-Music With Arm-based Sprint-Intensity Interval Training Among Children With Physical Disabilities Phase 1
Completed NCT04489498 - Comparison of Somatometric Characteristics Between Cerebral Palsy and Normal Children, Cross-sectional, Multi Center Study
Completed NCT03677193 - Biofeedback-enhanced Interactive Computer-play for Youth With Cerebral Palsy N/A
Recruiting NCT06450158 - Robot-assisted Training in Children With CP N/A
Completed NCT04093180 - Intensive Neurorehabilitation for Cerebral Palsy N/A
Completed NCT02909127 - The Pediatric Eating Assessment Tool
Not yet recruiting NCT06377982 - Human Umbilical Cord Blood Infusion in Patients With Cerebral Palsy Phase 1
Not yet recruiting NCT06007885 - Examining Capacity Building of Youth With Physical Disabilities to Pursue Participation Following the PREP Intervention. N/A
Not yet recruiting NCT03183427 - Corpus Callosum Size in Patients With Pineal Cyst N/A
Active, not recruiting NCT03078621 - Bone Marrow-Derived Stem Cell Transplantation for the Treatment of Cerebral Palsy Phase 1/Phase 2